Patents by Inventor Philip Huxley
Philip Huxley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7291612Abstract: The present invention relates to novel heterocyclic compounds, to methods for their preparation, to compositions containing them, and to methods and use for clinical treatment of medical conditions which may benefit from immunomodulation, including rheumatoid arthritis, multiple sclerosis, diabetes, asthma, transplantation, systemic lupus erythematosis and psoriasis. More particularly the present invention relates to novel heterocyclic compounds, which are CD80 antagonists capable of inhibiting the interactions between CD80 and CD28.Type: GrantFiled: May 30, 2006Date of Patent: November 6, 2007Assignee: Active Biotech A.B.Inventors: Ian Richard Matthews, Thomas Stephen Coutler, Chiara Ghiron, Chris James Brennan, Muhammed Kamal Uddin, Lars Olof Goran Pettersson, Dorthe da Graca Thrige, Philip Huxley
-
Publication number: 20060217411Abstract: The present invention relates to novel heterocyclic compounds, to methods for their preparation, to compositions containing them, and to methods and use for clinical treatment of medical conditions which may benefit from immunomodulation, including rheumatoid arthritis, multiple sclerosis, diabetes, asthma, transplantation, systemic lupus erythematosis and psoriasis. More particularly the present invention relates to novel heterocyclic compounds, which are CD80 antagonists capable of inhibiting the interactions between CD80 and CD28.Type: ApplicationFiled: May 30, 2006Publication date: September 28, 2006Inventors: Ian Matthews, Thomas Coulter, Chiara Ghiron, Chris Brennan, Muhammed Uddin, Lars Pettersson, Dorthe Thrige, Philip Huxley
-
Patent number: 7081456Abstract: The present invention relates to novel heterocyclic compounds, to methods for their preparation, to compositions containing them, and to methods and use for clinical treatment of medical conditions which may benefit from immunomodulation, including rheumatoid arthritis, multiple sclerosis, diabetes, asthma, transplantation, systemic lupus erythematosis and psoriasis. More particularly the present invention relates to novel heterocyclic compounds, which are CD80 antagonists capable of inhibiting the interactions between CD80 and CD28.Type: GrantFiled: November 21, 2003Date of Patent: July 25, 2006Assignee: Active Biotech ABInventors: Ian Richard Matthews, Thomas Stephen Coulter, Chiara Ghiron, Chris James Brennan, Muhammed Kamal Uddin, Lars Olof Göran Pettersson, Dorthe da Graca Thrige, Philip Huxley
-
Publication number: 20060035919Abstract: The present invention relates to novel heterocyclic compounds, to methods for their preparation, to compositions containing them, and to methods and use for clinical treatment of medical conditions which may benefit from immunomodulation, including rheumatoid arthritis, multiple sclerosis, diabetes, asthma, transplantation, systemic lupus erythematosis and psoriasis. More particularly, the present invention relates to novel heterocyclic compounds, which are CD80 antagonists capable of inhibiting the interactions between CD80 and CD28.Type: ApplicationFiled: December 12, 2003Publication date: February 16, 2006Inventors: Lan Matthews, Philip Huxley, Filippo Magaraci, Chris Brennan, Muhammed Uddin, Lars Pettersson, Dorthe Thrige
-
Publication number: 20050203118Abstract: The present invention relates to novel heterocyclic compounds, to methods for their preparation, to compositions containing them, and to methods and use for clinical treatment of medical conditions which may benefit from immunomodulation, including rheumatoid arthritis, multiple sclerosis, diabetes, asthma, transplantation, systemic lupus erythematosis and psoriasis. More particularly the present invention relates to novel heterocyclic compounds, which are CD80 antagonists capable of inhibiting the interactions between CD80 and CD28.Type: ApplicationFiled: November 21, 2003Publication date: September 15, 2005Applicant: ACTIVE BIOTECH ABInventors: Ian Matthews, Thomas Coulter, Chiara Ghiron, Chris Brennan, Muhammed Uddin, Lars Goran Pettersson, Dorthe Thrige, Philip Huxley
-
Patent number: 6790834Abstract: Compounds of formula I are disclosed wherein R4 is an ester or thioester group, and R, R1, R2, and R3 are as defined in the specification are inhibitors of rapidly dividing tumor cells.Type: GrantFiled: February 28, 2000Date of Patent: September 14, 2004Assignee: British Biotech Pharmaceuticals, Ltd.Inventors: Lindsey Ann Pearson, Andrew Paul Ayscough, Philip Huxley, Alan Drummond
-
Publication number: 20040116461Abstract: The present invention relates to novel heterocyclic compounds, to methods for their preparation, to compositions containing them, and to methods and use for clinical treatment of medical conditions which may benefit from immunomodulation, including rheumatoid arthritis, multiple sclerosis, diabetes, asthma, transplantation, systemic lupus erythematosis and psoriasis. More particularly the present invention relates to novel heterocyclic compounds, which are CD80 antagonists capable of inhibiting the interactions between CD80 and CD28.Type: ApplicationFiled: November 21, 2003Publication date: June 17, 2004Applicant: ACTIVE BIOTECH ABInventors: Ian Richard Matthews, Thomas Stephen Coulter, Chiara Ghiron, Chris James Brennan, Muhammed Kamal Uddin, Lars Olof Goran Pettersson, Dorthe da Graca Thrige, Philip Huxley
-
Patent number: 6569847Abstract: This invention relates to substituted azetidin-2-ones and to pharmaceutical compositions containing such compounds. Their use in medicine as inhibitors of cysteine proteases, particularly the cathepsins is also described. The invention includes a compound of formula (I), Y represents —C(O)— or —S(O2)—; R represents an allyl (ie CH2═CHCH2—) group or a radical. R1 represents —OCOR5, —OR5, —SR5, —S(O)R5, or —S(O)2R5; R2 represents a radical. R3 represents —OR5 or R5; or a pharmaceutically acceptable salt, hydrate or solvate thereof.Type: GrantFiled: October 5, 2001Date of Patent: May 27, 2003Assignee: NAEJA Pharmaceuticals Inc.Inventors: Rajeshwar Singh, Andhe V. Narender Reddy, Jadwiga Kaleta, Ronald G. Micetich, Mark Whittaker, Philip Huxley
-
Patent number: 6462023Abstract: The present invention provide compounds exemplified by 2(R or S)-[2R-(S-Hydroxy-hydroxycarbamoyl-methyl)-4-methyl-pentanoylamine]-2-phenyl-ethanoic acid cyclopentyl ester; 2(R or S)-(3S-Hydroxycarbamoyl-2R-isobutyl-hex-5-enoylamino)-2-phenylethanoic acid isopropyl ester; 2(R or S)-[2R-(S-Hydroxycarbamoyi-methoxy-methyl)-4-methyl-pentanoylamino]-3-phenylethanoic acid cyclopentyl ester; 2(R or S)-(3S-Hydroxycarbamoyl-2R-isobutyl-hex-5-enoylamino)-2-(4-methoxyphenyl)ethanoic acid cyclopentyl ester; 2(R or S)-(3S-Hydroxycarbamoyl-2R-isobutyl-hex-5-enoylamino)-2-(thien-2-yl)ethanoic acid cyclopentyl ester; and 2(R or S)-(3S-Hydroxycarbamoyl-2R-isobutyl-hex-5-enoylamino)-2-(thien-3-yl)ethanoic acid cyclopentyl ester are cytostatic agents. Methods of treating proliferative cell growth disorders as well a methods of inhibiting hyper-proliferative cells are also disclosed.Type: GrantFiled: June 19, 1998Date of Patent: October 8, 2002Assignee: British Biotech Pharmaceuticals, Ltd.Inventors: Lindsey Ann Pearson, Andrew Paul Ayscough, Philip Huxley, Alan Drummond
-
Patent number: 6169075Abstract: Compounds of formula 1 wherein R4 is an ester or thioester group, and R, R1, R2 and R3 are as defined in the specification are inhibitors of rapidly dividing tumour cells.Type: GrantFiled: September 8, 1997Date of Patent: January 2, 2001Assignee: British Biotech Pharmaceuticals LimitedInventors: Lindsey Ann Pearson, Andrew Paul Ayscough, Philip Huxley, Alan Hastings Drummond
-
Patent number: 5917090Abstract: The invention is directed to therapeutically active hydroxamic acid derivatives of formula (I): ##STR1## wherein the substituents are as defined in the specification. These therapeutically active hydroxamic acid derivatives have high intrinsic activity against a broad spectrum of matrix metalloproteinases (MMPs), good oral bioavailability, and additionally inhibit tissue necrosis factor (TNF) production.Type: GrantFiled: December 19, 1997Date of Patent: June 29, 1999Assignee: British Biotech Pharmaceuticals Ltd.Inventors: Philip Huxley, Fionna Mitchell Martin, Andrew Miller, Zoe Marie Spavold
-
Patent number: 5742796Abstract: A graphics subsystem which permits single buffered windows to exist in a double buffered system. Thus ALL the pixels on the screen are ultimately double buffered, but the single buffered should not appear to be double buffered. To support the single buffered windows, certain write operations are modified to write the same half-word of data into both the front and back half-words of an addressed location. This permits non-double buffered windows to remain correct when the RAMDAC.TM. is manipulated to swap buffers.Type: GrantFiled: March 24, 1995Date of Patent: April 21, 1998Assignee: 3Dlabs Inc. Ltd.Inventor: Philip Huxley
-
Patent number: 4727075Abstract: The invention relates to novel pyrimidine derivatives of the general formula ##STR1## wherein A is phenyl, phenoxyphenyl, phenylthiophenyl, biphenyl or naphthyl R.sub.a, R.sub.b and R.sub.c are each independently hydrogen, halogen, cyano, nitro, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, C.sub.1 -C.sub.4 haloalkyl or C.sub.1 -C.sub.4 haloalkoxy andX is one of the following bridge elements ##STR2## in which formulae R.sub.1 and R.sub.2 are each independently of the other hydrogen, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 haloalkyl or CH.sub.2 O--C.sub.1 -C.sub.4 alkyl, R.sub.4 is hydrogen, C.sub.1 -C.sub.4 alkyl or CH.sub.2 OH and R.sub.3, R.sub.5 and R.sub.6 are each independently hydrogen or C.sub.1 -C.sub.4 alkyl,and to the acid addition salts thereof.The novel compounds possess microbicidal properties and are suitable in particular for controlling phytopathogenic microorganisms.Type: GrantFiled: August 18, 1986Date of Patent: February 23, 1988Assignee: Ciba-Geigy CorporationInventors: Wolfgang Eckhardt, Philip Huxley